Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
- 10 September 2009
- journal article
- research article
- Published by Elsevier BV in Lung Cancer
- Vol. 68 (3), 455-459
- https://doi.org/10.1016/j.lungcan.2009.07.016
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute
This publication has 34 references indexed in Scilit:
- Mesothelin targeted cancer immunotherapyEuropean Journal Of Cancer, 2007
- Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinomaPathology International, 2007
- Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic PerfusionAnnals of Surgical Oncology, 2006
- Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian CancerClinical Cancer Research, 2006
- Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas but Not in Normal Pancreas and Chronic PancreatitisAmerican Journal of Clinical Pathology, 2005
- New tumor markers: CA125 and beyondInternational Journal of Gynecologic Cancer, 2005
- Value of Mesothelin Immunostaining in the Diagnosis of MesotheliomaLaboratory Investigation, 2003
- Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME‐1 expressionHistopathology, 1997
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992
- Tissue Distribution of a Coelomic- Epithelium-Related Antigen Recognized by the Monoclonal Antibody OC125International Journal of Gynecological Pathology, 1983